Trade Pluri Inc. - PLUR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0326 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 1.1187 |
| Open* | 1.1187 |
| 1-Year Change* | -33.01% |
| Day's Range* | 1.0587 - 1.1287 |
| 52 wk Range | 0.65-2.21 |
| Average Volume (10 days) | 30.38K |
| Average Volume (3 months) | 1.47M |
| Market Cap | 34.94M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 32.66M |
| Revenue | 321.00K |
| EPS | -1.12 |
| Dividend (Yield %) | N/A |
| Beta | 1.60 |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 1.0587 | -0.0600 | -5.36% | 1.1187 | 1.1287 | 1.0587 |
| Feb 2, 2023 | 1.1187 | 0.0200 | 1.82% | 1.0987 | 1.1187 | 1.0787 |
| Jan 27, 2023 | 1.1187 | -0.0299 | -2.60% | 1.1486 | 1.1586 | 1.1087 |
| Jan 26, 2023 | 1.1287 | 0.0100 | 0.89% | 1.1187 | 1.1287 | 1.1187 |
| Jan 25, 2023 | 1.0887 | 0.0000 | 0.00% | 1.0887 | 1.0887 | 1.0887 |
| Jan 24, 2023 | 1.1586 | 0.0000 | 0.00% | 1.1586 | 1.1686 | 1.1586 |
| Jan 20, 2023 | 1.1586 | -0.0400 | -3.34% | 1.1986 | 1.1986 | 1.1586 |
| Jan 19, 2023 | 1.2286 | 0.0200 | 1.65% | 1.2086 | 1.2585 | 1.1686 |
| Jan 18, 2023 | 1.2785 | 0.0599 | 4.92% | 1.2186 | 1.2785 | 1.2186 |
| Jan 17, 2023 | 1.2585 | 0.0799 | 6.78% | 1.1786 | 1.3285 | 1.1786 |
| Jan 13, 2023 | 1.2086 | 0.1399 | 13.09% | 1.0687 | 1.3984 | 1.0687 |
| Jan 12, 2023 | 1.0288 | 0.0000 | 0.00% | 1.0288 | 1.0687 | 1.0288 |
| Jan 11, 2023 | 1.0088 | -0.0200 | -1.94% | 1.0288 | 1.0288 | 1.0088 |
| Jan 9, 2023 | 1.0288 | 0.0300 | 3.00% | 0.9988 | 1.0588 | 0.9988 |
| Jan 6, 2023 | 0.9986 | 0.0435 | 4.55% | 0.9551 | 1.0288 | 0.9551 |
| Jan 5, 2023 | 0.9550 | -0.0299 | -3.04% | 0.9849 | 0.9850 | 0.9489 |
| Jan 4, 2023 | 0.9987 | 0.0039 | 0.39% | 0.9948 | 0.9988 | 0.9948 |
| Jan 3, 2023 | 0.9916 | 0.0067 | 0.68% | 0.9849 | 0.9985 | 0.9788 |
| Dec 30, 2022 | 0.9352 | -0.0065 | -0.69% | 0.9417 | 0.9489 | 0.9352 |
| Dec 29, 2022 | 0.9277 | -0.0175 | -1.85% | 0.9452 | 0.9551 | 0.9203 |
Pluri Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
| Revenue | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
| Cost of Revenue, Total | 0.1 | 0 | 0.002 | 0.002 | 0 | 0 |
| Gross Profit | 2.747 | 0 | 0.048 | 0.052 | 0.023 | 0 |
| Total Operating Expense | 26.166 | 28.019 | 33.781 | 35.586 | 29.499 | 50.623 |
| Selling/General/Admin. Expenses, Total | 6.486 | 6.927 | 11.193 | 9.157 | 7.922 | 20.557 |
| Research & Development | 20.85 | 21.972 | 24.478 | 12.841 | 21.643 | 13.47 |
| Depreciation / Amortization | 2.006 | 2.029 | 1.893 | 1.841 | 1.453 | 1.252 |
| Other Operating Expenses, Total | -3.276 | -2.909 | -3.785 | 11.745 | -1.519 | 15.344 |
| Operating Income | -23.319 | -28.019 | -33.731 | -35.532 | -29.476 | -50.623 |
| Interest Income (Expense), Net Non-Operating | 0.109 | 0.272 | 8.542 | 0.105 | 0.356 | 0.781 |
| Other, Net | -0.036 | -0.067 | -0.937 | 0.12 | -0.032 | -0.023 |
| Net Income Before Taxes | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Net Income After Taxes | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Net Income Before Extra. Items | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Net Income | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Income Available to Common Excl. Extra. Items | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Income Available to Common Incl. Extra. Items | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Diluted Net Income | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Diluted Weighted Average Shares | 7.9548 | 8.74262 | 10.5877 | 1.23329 | 18.1973 | 28.1136 |
| Diluted EPS Excluding Extraordinary Items | -2.92226 | -3.18143 | -2.46759 | -28.6283 | -1.602 | -1.77369 |
| Dividends per Share - Common Stock Primary Issue | 0 | |||||
| Diluted Normalized EPS | -2.85237 | -3.12149 | -2.38995 | -28.1158 | -1.5688 | -1.74709 |
| Q3 2021 | Q4 2021 | Q1 2021 | Q2 2021 | Q3 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0.234 |
| Revenue | 0 | 0 | 0.234 | ||
| Cost of Revenue, Total | 0 | 0 | |||
| Gross Profit | 0 | 0 | |||
| Total Operating Expense | 14.225 | 14.587 | 11.441 | 10.795 | 10.709 |
| Selling/General/Admin. Expenses, Total | 6.559 | 6.102 | 5.088 | 4.288 | 4.553 |
| Research & Development | 7.824 | 8.507 | 6.391 | 6.541 | 6.273 |
| Other Operating Expenses, Total | -0.158 | -0.022 | -0.038 | -0.034 | -0.117 |
| Operating Income | -14.225 | -14.587 | -11.441 | -10.795 | -10.475 |
| Interest Income (Expense), Net Non-Operating | -0.029 | 0.019 | 0.009 | -0.145 | 0.557 |
| Net Income Before Taxes | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Net Income After Taxes | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Net Income Before Extra. Items | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Net Income | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Income Available to Common Excl. Extra. Items | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Income Available to Common Incl. Extra. Items | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Diluted Net Income | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
| Diluted Weighted Average Shares | 29.6172 | 31.6441 | 32.0008 | 32.1363 | 32.2616 |
| Diluted EPS Excluding Extraordinary Items | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 35.596 | 29.016 | 32.036 | 26.371 | 48.461 | 67.371 |
| Cash and Short Term Investments | 32.208 | 26.106 | 29.9 | 23.705 | 45.784 | 64.95 |
| Cash & Equivalents | 6.223 | 4.707 | 8.821 | 4.106 | 8.27 | 31.241 |
| Short Term Investments | 25.985 | 21.399 | 21.079 | 19.599 | 37.514 | 33.709 |
| Total Receivables, Net | 2.481 | 1.174 | 0.847 | 1.421 | 1.61 | 1.49 |
| Accounts Receivable - Trade, Net | 2.251 | 1.036 | 0.69 | 1.243 | 1.248 | 1.108 |
| Prepaid Expenses | 0.3 | 0.882 | 0.602 | 0.532 | 0.445 | 0.333 |
| Other Current Assets, Total | 0.607 | 0.854 | 0.687 | 0.713 | 0.622 | 0.598 |
| Total Assets | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
| Property/Plant/Equipment, Total - Net | 9.216 | 7.277 | 5.678 | 3.838 | 3.775 | 2.227 |
| Property/Plant/Equipment, Total - Gross | 17.183 | 16.507 | 16.893 | 17.004 | 18.437 | 18.259 |
| Accumulated Depreciation, Total | -7.967 | -9.23 | -11.215 | -13.166 | -14.662 | -16.032 |
| Long Term Investments | 0.363 | 0.403 | 0.383 | 0.398 | 12.653 | 23.269 |
| Other Long Term Assets, Total | 0.766 | 0.838 | 0.863 | 0.703 | 0.643 | 0.671 |
| Total Current Liabilities | 5.775 | 5.414 | 8.548 | 8.158 | 7.987 | 11.517 |
| Accounts Payable | 2.705 | 1.966 | 3.261 | 2.281 | 1.968 | 2.526 |
| Accrued Expenses | 2.819 | 3.106 | 4.164 | 5.637 | 5.893 | 8.951 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.251 | 0.342 | 1.123 | 0.24 | 0.126 | 0.04 |
| Total Liabilities | 7.785 | 7.283 | 10.453 | 9.489 | 9.431 | 36.387 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 23.85 |
| Other Liabilities, Total | 2.01 | 1.869 | 1.905 | 1.331 | 1.444 | 1.02 |
| Total Equity | 38.156 | 30.251 | 28.507 | 21.821 | 56.101 | 57.151 |
| Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | ||
| Additional Paid-In Capital | 198.432 | 217.822 | 244.203 | 272.824 | 336.257 | 387.172 |
| Retained Earnings (Accumulated Deficit) | -161.757 | -189.571 | -215.697 | -251.004 | -280.156 | -330.021 |
| Unrealized Gain (Loss) | 1.48 | 1.48 | 8.44 | |||
| Other Equity, Total | 0 | 0.519 | -8.44 | |||
| Total Liabilities & Shareholders’ Equity | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
| Total Common Shares Outstanding | 8.0269 | 9.69388 | 11.3566 | 15.0829 | 25.4927 | 31.9578 |
| Long Term Debt | 23.85 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 49.82 | 67.371 | 62.826 | 60.153 | 64.313 |
| Cash and Short Term Investments | 47.37 | 64.95 | 60.671 | 58.183 | 61.98 |
| Cash & Equivalents | 12.265 | 31.241 | 14.611 | 18.715 | 23.791 |
| Short Term Investments | 35.105 | 33.709 | 46.06 | 39.468 | 38.189 |
| Other Current Assets, Total | 2.45 | 2.421 | 2.155 | 1.97 | 2.333 |
| Total Assets | 79.174 | 93.538 | 83.747 | 81.184 | 79.127 |
| Property/Plant/Equipment, Total - Net | 2.713 | 2.227 | 1.749 | 9.331 | 9.14 |
| Long Term Investments | 25.937 | 23.269 | 18.483 | 10.965 | 4.235 |
| Other Long Term Assets, Total | 0.704 | 0.671 | 0.689 | 0.735 | 1.439 |
| Total Current Liabilities | 9.916 | 11.517 | 10.365 | 9.595 | 7.822 |
| Accounts Payable | 2.11 | 2.526 | 3.723 | 4.058 | 3.942 |
| Accrued Expenses | 5.613 | 6.575 | 6.642 | 5.537 | 3.88 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 2.193 | 2.416 | |||
| Total Liabilities | 11.038 | 36.387 | 34.84 | 41.344 | 41.034 |
| Total Long Term Debt | 0 | 23.85 | 23.444 | 23.158 | 22.924 |
| Other Liabilities, Total | 1.122 | 1.02 | 1.031 | 8.591 | 8.238 |
| Total Equity | 68.136 | 57.151 | 48.907 | 39.84 | 38.0933 |
| Additional Paid-In Capital | 383.589 | 387.172 | 390.36 | 392.233 | 400.351 |
| Retained Earnings (Accumulated Deficit) | -315.453 | -330.021 | -341.453 | -352.393 | -362.258 |
| Total Liabilities & Shareholders’ Equity | 79.174 | 93.538 | 83.747 | 81.184 | 79.1273 |
| Total Common Shares Outstanding | 31.7402 | 31.9578 | 32.0969 | 32.2251 | 32.3424 |
| Total Receivables, Net | 0 | ||||
| Accounts Receivable - Trade, Net | 0 | ||||
| Current Port. of LT Debt/Capital Leases | 0 | ||||
| Long Term Debt | 23.85 | 23.444 | 23.158 | 22.924 | |
| Common Stock | 0.00032 | 0.00032 | |||
| Other Equity, Total | -0.00032 | ||||
| Minority Interest | 2.05 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
| Cash From Operating Activities | -18.522 | -21.611 | -21.38 | -29.453 | -26.369 | -30.91 |
| Cash From Operating Activities | 2.15 | 2.177 | 2.018 | 1.962 | 1.57 | 1.37 |
| Non-Cash Items | 3.498 | 4.174 | -1.025 | 5.146 | 2.562 | 13.968 |
| Cash Taxes Paid | 0.066 | 0.028 | 0.027 | 0.01 | 0.01 | |
| Changes in Working Capital | -0.924 | -0.148 | 3.753 | -1.254 | -1.349 | 3.617 |
| Cash From Investing Activities | 1.312 | 4.355 | 5.681 | 1.17 | -30.458 | -7.265 |
| Capital Expenditures | -1.75 | -0.378 | -0.342 | -0.239 | -0.27 | -0.373 |
| Other Investing Cash Flow Items, Total | 3.062 | 4.733 | 6.023 | 1.409 | -30.188 | -6.892 |
| Cash From Financing Activities | 0.807 | 15.797 | 19.921 | 23.582 | 60.87 | 61.402 |
| Issuance (Retirement) of Stock, Net | 0.807 | 15.728 | 19.833 | 23.475 | 60.87 | 36.953 |
| Net Change in Cash | -16.403 | -1.459 | 4.222 | -4.701 | 4.043 | 22.609 |
| Financing Cash Flow Items | 0.069 | 0.088 | 0.107 | 0 | ||
| Issuance (Retirement) of Debt, Net | 24.449 | |||||
| Foreign Exchange Effects | -0.618 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -35.297 | -49.865 | -11.432 | -22.372 | -32.29 |
| Cash From Operating Activities | -21.313 | -30.91 | -8.789 | -18.652 | -28.074 |
| Cash From Operating Activities | 1.034 | 1.37 | 0.337 | 0.664 | 0.915 |
| Non-Cash Items | 10.382 | 13.968 | 3.188 | 6.1 | 7.782 |
| Cash Taxes Paid | 0.008 | ||||
| Changes in Working Capital | 2.568 | 3.617 | -0.882 | -3.044 | -4.481 |
| Cash From Investing Activities | -12.057 | -7.265 | -7.24 | 7.075 | 14.738 |
| Capital Expenditures | -0.331 | -0.373 | -0.015 | -0.044 | -0.081 |
| Other Investing Cash Flow Items, Total | -11.726 | -6.892 | -7.225 | 7.119 | 14.819 |
| Cash From Financing Activities | 36.992 | 61.402 | 0 | 0 | 7.5 |
| Issuance (Retirement) of Stock, Net | 36.992 | 36.953 | 0 | 0 | 0 |
| Net Change in Cash | 3.622 | 22.609 | -16.62 | -12.616 | -6.908 |
| Issuance (Retirement) of Debt, Net | 24.449 | ||||
| Foreign Exchange Effects | -0.618 | -0.591 | -1.039 | -1.072 | |
| Financing Cash Flow Items | 7.5 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Yanay (Yaky) | Individual Investor | 3.2937 | 1075620 | 396790 | 2022-12-22 | LOW |
| Regals Capital Management, L.P. | Investment Advisor | 3.2824 | 1071938 | 1071938 | 2022-01-24 | |
| Aberman (Zalman) | Individual Investor | 2.5434 | 830604 | -2000 | 2022-12-20 | LOW |
| Slager (David M) | Individual Investor | 1.8774 | 613100 | 613100 | 2022-01-24 | HIGH |
| Meitav Dash Investments Ltd. | Investment Advisor | 0.5132 | 167593 | 0 | 2022-09-30 | LOW |
| Nia Impact Capital | Investment Advisor | 0.4071 | 132947 | -318394 | 2022-09-30 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.3235 | 105657 | -174105 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.3197 | 104400 | -2900 | 2022-09-30 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.3142 | 102600 | -10000 | 2022-09-30 | LOW |
| Nikko Asset Management Americas, Inc. | Investment Advisor/Hedge Fund | 0.2574 | 84056 | -20865 | 2021-12-31 | LOW |
| Franco-Yehuda (Chen) | Individual Investor | 0.225 | 73466 | 6875 | 2022-12-21 | LOW |
| Green Alpha Advisors, LLC | Investment Advisor | 0.1794 | 58603 | 2377 | 2022-12-31 | HIGH |
| Values First Advisors, Inc. | Investment Advisor | 0.1398 | 45653 | -2677 | 2022-12-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1211 | 39544 | 0 | 2022-12-31 | LOW |
| Jane Street Capital, L.L.C. | Research Firm | 0.1102 | 35986 | -46524 | 2022-09-30 | HIGH |
| Group One Trading, L.P. | Research Firm | 0.0877 | 28638 | -5900 | 2022-09-30 | HIGH |
| Zürcher Kantonalbank (Asset Management) | Bank and Trust | 0.0842 | 27497 | -137 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0771 | 25169 | 0 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.0625 | 20412 | -120303 | 2022-09-30 | HIGH |
| Archford Capital Strategies, LLC | Investment Advisor | 0.0401 | 13091 | 0 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group +485000+
Traders
65000+
Active clients monthly
$48000000+
Monthly investing volume
$28000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Pluri Inc. Company profile
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Financial summary
BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.
Equity composition
Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.
| Industry: | Biotechnology & Medical Research (NEC) |
MATAM Advanced Technology Park
Building #5
3508409
Income Statement
- Annual
- Quarterly
News
S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023
British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision
Bank of England remains a dovish hiker. GBP at risk of another dovish twist
15:13, 1 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com